A practical reference on peptide analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-07. Anything still debated is marked as such rather than presented as settled.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
Schumer did an episode (#154) of WTF with Marc Maron podcast on March 3, 2011, in which she discusses her early life in more detail. Schumer has appeared in roles on the NBC comedy series 30 Rock, the Adult Swim mockumentary series Delocated, and the two HBO series, Curb Your Enthusiasm and Girls. She was also a frequent guest on The Howard Stern Show and the Opie and Anthony radio show. Schumer released a stand-up comedy album, Cutting, in 2011. Her stand-up comedy special Mostly Sex Stuff premiered on Comedy Central on August 18, 2012, to positive reviews. Schumer said in February 2012, "I don't like the observational stuff. I like tackling the stuff nobody else talks about, like the darkest, most serious thing about yourself. I talk about life and sex and personal stories and stuff everybody can relate to, and some can't." She acted in three films in 2012: the independent comedy Price Check, the comedy-drama Seeking a Friend for the End of the World, and the independent comedy Sleepwalk with Me. Schumer also appeared on The Comedy Central Roast of Charlie Sheen in September 2011, and The Comedy Central Roast of Roseanne Barr in August 2012. In June 2012, Schumer began work on a sketch comedy series for Comedy Central. The show included single-camera vignettes of Schumer playing "heightened versions" of herself. The vignettes are linked together with footage of Schumer's stand-up.
== Classification == Skeletons can be defined by several attributes. Solid skeletons consist of hard substances, such as bone, cartilage, or cuticle. These can be further divided by location; internal skeletons are endoskeletons, and external skeletons are exoskeletons. Skeletons may also be defined by rigidity, where pliant skeletons are more elastic than rigid skeletons. Fluid or hydrostatic skeletons do not have hard structures like solid skeletons, instead functioning via pressurized fluids. Hydrostatic skeletons are always internal.
==== Particles ==== Particles in UPW have always presented a major problem for semiconductor manufacture, as any particle landing on a silicon wafer can bridge the gap between the electrical pathways in the semiconductor circuitry. Particle count can be monitored in ultrapure water using laser-based particle counting systems or, for diagnostics, scanning electron microscopy.
Sources: en.wikipedia.org
In general USPTO rejections on the sole grounds of the invention's being "inoperative" are rare, since such rejections need to demonstrate "proof of total incapacity", and cases where those rejections are upheld in a Federal Court are even rarer: nevertheless, in 2000, a rejection of a cold fusion patent was appealed in a Federal Court and it was upheld, in part on the grounds that the inventor was unable to establish the utility of the invention. A U.S. patent might still be granted when given a different name to disassociate it from cold fusion, though this strategy has had little success in the US: the same claims that need to be patented can identify it with cold fusion, and most of these patents cannot avoid mentioning Fleischmann and Pons' research due to legal constraints, thus alerting the patent reviewer that it is a cold-fusion-related patent. David Voss said in 1999 that some patents that closely resemble cold fusion processes, and that use materials used in cold fusion, have been granted by the USPTO. The inventor of three such patents had his applications initially rejected when they were reviewed by experts in nuclear science; but then he rewrote the patents to focus more on the electrochemical parts so they would be reviewed instead by experts in electrochemistry, who approved them. When asked about the resemblance to cold fusion, the patent holder said that it used nuclear processes involving "new nuclear physics" unrelated to cold fusion.
=== Mexico === The Secretariat of National Defense issues the "Individual Soldiers Daily Combat Meal" box (Spanish: Ración Diaria Individual de Combate). It is packaged in an olive green and black plastic box with the contents printed on the front; the box contains three individual meal packs containing meals providing 3,640 to 4,030 kcal (15,200 to 16,900 kJ) which are meant to sustain a soldier for one day. Each individual meal package contains two main retort pouches which are meant to be eaten with each other. The first retort pouch usually contains a meat product (such as beef, pork, sausage, fish, ham, seafood, chicken, tuna, bacon, or other meats which are usually mixed with a flavoring sauce and vegetables) the second retort pouch contains a staple food (rice, hominy, noodles, beans, pasta, eggs, or more vegetables). Each meal package also contains salt, spices, condensed milk, cream, butter, chorizo spread, dried fruit or preserves, bread, crackers, sugar, custard, cookies, canned fish, cocoa mix, nuts, chocolate or other candies, vitamins, a large pouch of drinking water, a pouch of Jumex fruit juice or Coca-Cola, biodegradable napkins and utensils, and water purification tablets. Some meal packages do not contain the two main retort pouches and instead contain a single larger pouch with a finished meal such as tamales or steak and eggs but, these are usually only available when close to a base or when the military is operating in an urban area.
=== Construction === Spent diatomaceous earth from the brewing process can be added to ceramic mass for the production of red bricks with higher open porosity. Diatomaceous earth is considered a prominent inorganic non-metallic material that can be used for the production of various ceramics, including production of porous ceramics under low temperature hydrothermal technology.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.